Print

HVTN 115

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of EnvSeq-1 Envs Adjuvanted With GLA-SE, Administered Alone or With DNA Mosaic-Tre Env, in Healthy, HIV-Uninfected Adult Participants

Trial Details:

I Ongoing
National Institute of Allergy and Infectious Diseases (NIAID) August 01, 2017
CH505 sequenced Envs ,DNA Mosaic-Tre Env CH505 sequenced Envs Clade C; DNA mosaic env
CH505 sequenced Envs Protein
DNA Mosaic-Tre Env DNA
GLA-SE
USA 132
NCT03220724
https://clinicaltrials.gov/ct2/show/NCT03220724